Lights and Shadows in Immuno-Oncology Drug Development.
Loading...
Embargo End Date
ICR Authors
Authors
Bergamino Sirvén, M
Pernas, S
Cheang, MCU
Pernas, S
Cheang, MCU
Document Type
Journal Article
Date
2021-02-09
Date Accepted
2021-02-05
Abstract
The rapidly evolving landscape of immuno-oncology (IO) is redefining the treatment of a number of cancer types. IO treatments are becoming increasingly complex, with different types of drugs emerging beyond checkpoint inhibitors. However, many of the new drugs either do not progress from phase I-II clinical trials or even fail in late-phase trials. We have identified at least five areas in the development of promising IO treatments that should be redefined for more efficient designs and accelerated approvals. Here we review those critical aspects of IO drug development that could be optimized for more successful outcome rates in all cancer types. It is important to focus our efforts on the mechanisms of action, types of response and adverse events of these novel agents. The use of appropriate clinical trial designs with robust biomarkers of response and surrogate endpoints will undoubtedly facilitate the development and subsequent approval of these drugs. Further research is also needed to establish biomarker-driven strategies to select which patients may benefit from immunotherapy and identify potential mechanisms of resistance.
Citation
Cancers, 2021, 13 (4)
Source Title
Publisher
MDPI
ISSN
2072-6694
eISSN
2072-6694
Collections
Research Team
Genomic Analysis – Clinical Trials
Genomic Analysis – Clinical Trials
Genomic Analysis – Clinical Trials